Examples Of Selected Projects.
Selected examples are fully anonymised. Company names, product identifiers and strategic findings are intentionally withheld. Project imagery is illustrative and does not represent a client, product or confidential asset.
Meaningful answers.
Intelligence work spanning diverse indications and development stages.
Grapon has supported clinical, commercial and portfolio decisions across oncology, nephrology, infectious diseases, immunology, neurology, rare diseases and vaccines. Our work ranges from asset-level clinical intelligence and competitor monitoring to treatment-pathway assessment, launch planning and portfolio strategy.
The examples below are anonymised. Client names, asset identifiers, source identities and strategic conclusions remain confidential. Project visuals are illustrative and are used only to indicate the therapeutic area.
Clinical · commercial · market access
Meningococcal vaccine portfolio strategy
Intelligence questionHow could a new pentavalent vaccine programme be sequenced across infant and adolescent populations, and what clinical, regulatory and market factors could shape adoption?
Explore project scopeClose project details+
Clinical · commercial execution
Prostate cancer radioligand therapy
Intelligence questionWhat was constraining treatment conversion as radioligand therapy expanded, and how were capacity, referral pathways and competitive treatment sequencing shaping execution?
Explore project scopeClose project details+
Formulation · regulatory · commercial
Oral CGRP reformulation
Intelligence questionWas the programme converging on a future formulation, and what could formulation, manufacturing and regulatory changes mean for development and commercial positioning?
Explore project scopeClose project details+
Regulatory · launch strategy
Fibrinogen market intelligence
Intelligence questionWhen could manufacturers progress filings, approvals and launches for new fibrinogen presentations across the US and Europe, and what could alter the timing?
Explore project scopeClose project details+
Competitive · portfolio strategy
HIV portfolio and dosing strategy
Intelligence questionHow could oral and long-acting dosing formats shape patient segmentation, switching, persistence, geographic strategy and the roles of products within a portfolio?
Explore project scopeClose project details+
Clinical · competitive intelligence
IgAN competitive landscape
Intelligence questionHow could an evolving IgA nephropathy treatment landscape change development sequencing, evidence differentiation and commercial planning?
Explore project scopeClose project details+
“Thank you for the interim, this is a very good start, and you have obtained useful intelligence that directly addresses the client’s main hypotheses.”
Have A Similar Intelligence Question?
Tell us what you are trying to understand.